Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer Journal Article

   


Authors: Schoenfeld, A. J.; Antonia, S. J.; Awad, M. M.; Felip, E.; Gainor, J.; Gettinger, S. N.; Hodi, F. S.; Johnson, M. L.; Leighl, N. B.; Lovly, C. M.; Mok, T.; Perol, M.; Reck, M.; Solomon, B.; Soria, J. C.; Tan, D. S. W.; Peters, S.; Hellmann, M. D.
Article Title: Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
Abstract: Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of persistent antitumor immunity that could be re-harnessed by investigational immunotherapies. The absence of a consistent clinical definition of AR to PD-(L)1 blockade and lack of uniform criteria for ensuing enrollment in clinical trials remains a major barrier to progress; such clinical definitions have advanced biologic and therapeutic discovery. We examine the considerations and potential controversies in developing a patient-level definition of AR in NSCLC treated with PD-(L)1 blockade. Taking into account the specifics of NSCLC biology and corresponding treatment strategies, we propose a practical, clinical definition of AR to PD-(L)1 blockade for use in clinical reports and prospective clinical trials. Patients should meet the following criteria: received treatment that includes PD-(L)1 blockade; experienced objective response on PD-(L)1 blockade (inclusion of a subset of stable disease will require future investigation); have progressive disease occurring within 6 months of last anti-PD-(L)1 antibody treatment or rechallenge with anti-PD-(L)1 antibody in patients not exposed to anti-PD-(L)1 in 6 months. © 2021 European Society for Medical Oncology
Keywords: lung cancer; immunotherapy; acquired resistance; checkpoint inhibitor; pd-(l)1 blockade
Journal Title: Annals of Oncology
Volume: 32
Issue: 12
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2021-12-01
Start Page: 1597
End Page: 1607
Language: English
DOI: 10.1016/j.annonc.2021.08.2151
PROVIDER: scopus
PUBMED: 34487855
PMCID: PMC12013006
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119392820&doi=10.1016%2fj.annonc.2021.08.2151&partnerID=40&md5=f1cca47c9eb20d897a9c48c7a879f498
Notes: Article -- Export Date: 1 December 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Matthew David Hellmann
    412 Hellmann
  2. Adam Jacob Schoenfeld
    132 Schoenfeld
Related MSK Work